Wednesday, July 15, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

Q3 2021’s health tech funding blows previous years out of the water

The health tech investment train maintained its brisk pace as two new venture capital investment reports show even more record-breaking fundraises through the third quarter of 2021.

The data, from Rock Health and StartUp Health, outline third-quarter and full-year funding records—although both sources indicated a slight dip in month-over-month raises.

For example, Rock Health’s report on industrywide digital health funding pegged the third quarter’s fundraising total at $6.7 billion across 169 deals.

This was a fair gain over Q3 2020’s $4.2 billion but a pullback from the $8.2 billion of this year’s second quarter. Rock Health attributed the short-term decline to a dip in overall deal volume as well as a slowdown in $100 million-plus “mega deals.”

Still, the addition of digital health’s second-largest-ever fundraising quarter was more than enough to put 2021 squarely in the lead for digital health’s best-funded year to date.

By Rock Health’s tally, the first nine months alone have brought in a total $21.3 billion across 541 investment deals, dwarfing the $14.6 billion record of 2020.

Source: Fierce Healthcare

https://www.fiercehealthcare.com/digital-health/health-tech-s-q3-2021-funding-blows-previous-years-out-water-rock-health-startup

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

Policy Shift in Peptide Regulation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...

Read more

Join Our Newsletter!